Prof. Serge Ferrari (Geneva University Hospital, Switzerland) presented the latest findings and insights into treatment of osteoporosis, monitoring treatment effects, the benefits of preventing fractures, and emerging concepts based on recent publications and evaluation of clinical trials .
Osteoporosis therapy is focused on quickly preventing fragility fractures in individuals at risk. Other goals are restoring bone mineral density and, on the longer term, bone strength. Both antiresorptive agents (e.g. zoledronate, denosumab) and anabolics (e.g. teriparatide, romosozumab) have been shown to reduce the risk of vertebral fractures within one year, whereas the benefits on non-vertebral fractures may take about 2 years to appear. “Fracture risk algorithms that combine clinical risk factors and bone mineral density are now widely used in clinical practice to target high-risk individuals for treatment,” said Dr Ferrari. “However, this simple approach has be...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Unacceptable Pain Is Common in Patients with Psoriatic Arthritis Next Article
Support for Tocilizumab Use in Giant Cell Arteritis »
Table of Contents: EULAR 2019
Osteoarthritis and Osteoporosis
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.